Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Neurogene's stock falls in post-market trading after early data in Rett syndrome

6 months ago

Cell therapy startup's IPO plans thrown in limbo amid legal spat with investor Alcon

6 months ago

Updated: FDA approves Autolus’ CAR-T cell therapy for aggressive blood cancer

6 months ago

Gilead and Arcellx spotlight safety of multiple myeloma cell therapy, dose first patient in Phase 3

6 months ago

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

6 months ago

Exclusive: Blood stem cell therapy maker Garuda gets new CEO, adds $47M

6 months ago

Lyell Immunopharma to acquire ImmPACT Bio, cut top programs

7 months ago

BridgeBio shares promising results in trial of Canavan disease gene therapy

7 months ago

Roche returns to Dyno for its AAV tech with $50M upfront

7 months ago

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

7 months ago

Houston startup March Biosciences raises $28M to get CAR-T into Phase 2

7 months ago

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

7 months ago

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

7 months ago

Editas pivots away from ex vivo sickle cell therapy in favor of in vivo approach

7 months ago

AvenCell gets $112M to build switchable CAR-T therapies for ‘the last frontier’ of blood cancers

7 months ago

Regenxbio shares new mid-stage data for its wet AMD gene therapy

7 months ago

Apertura and Atalanta reduce headcount en route toward the clinic

7 months ago

RNA gene therapy startup Shape hunts for new CEO as Series C awaits

7 months ago

First patient who received engineered B cell therapy sees early promise for MPS I

7 months ago

MeiraGTx's stock rises on small Parkinson's gene therapy dataset

7 months ago

Pfizer details results from failed Phase 3 trial of Duchenne muscular dystrophy gene therapy

7 months ago

Immatics heads to Phase 3 with melanoma cell therapy, seeks to raise $150M

7 months ago

Purespring nabs $105M to take gene therapy into the clinic as IgAN field matures

7 months ago

Astellas places new bet on gene therapy in $50M upfront deal with UK startup

7 months ago

First page Previous page 2 3 456 7 8 Next page Last page